HALO

Halozyme Therapeutics, Inc.

About HALO

Halozyme Therapeutics, Inc. is a biopharma technology platform company. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine its ENHANZE drug delivery technology with the collaborators' compounds. The Company’s proprietary enzyme, rHuPH20, is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids. The Company’s commercially approved product, Hylenex recombinant (Hylenex), and its ENHANZE partners approved products and product candidates are based on rHuPH20. It also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technology that is designed to provide commercial or functional advantages. It has a commercial portfolio of proprietary products, including XYOSTED, TLANDO and NOCDURNA and partnered commercial products and ongoing product development programs with several pharmaceutical companies.

Buy US stocks in Australia starting with HALO. Open an account and start investing today!

Market Capitalisation

$4.71B

Price-earnings ratio

Dividend yield

0.00%

Volume

High today

$35.17

Low today

$33.25

Open price

$0.00

52-week high

$59.46

52-week low

$32.93

HALO FAQs

How much is one share of Halozyme Therapeutics, Inc.?

One share of Halozyme Therapeutics, Inc. is valued at $34.92.

What is the ticker symbol for Halozyme Therapeutics, Inc.?

The ticker symbol for Halozyme Therapeutics, Inc. is HALO.

How do I buy HALO shares in Australia?

To buy HALO stocks in Australia you'll need to open an account with a broker like Stake.
To do so follow these steps:

Sign up in minutes, all you need is some I.D.
Choose Stake Wall St
Deposit directly into your Stake wallet and you're ready to invest in HALO

What is the 52-week high for Halozyme Therapeutics, Inc. stock?

The Halozyme Therapeutics, Inc. 52-week high stock price is $59.46.

What is the 52-week low for Halozyme Therapeutics, Inc. stock?

The Halozyme Therapeutics, Inc. 52-week low stock price is $32.93.

What is the market capitalisation of Halozyme Therapeutics, Inc. HALO?

As of 21/03/2023 Halozyme Therapeutics, Inc. has a market cap of $4.7B.

Related Stocks

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.